InflaRx (IFRX)
Develops C5a-pathway medicines centered on oral izicopan for inflammatory and renal diseases.
$2.43
Pre-market+0.14 (+5.88%)
At close$2.30(+6.25%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions37 holders · as of Mar 31, 2026 | 13.05% | 18.87M ADS | |
| Insiders6 holders · as of Mar 18, 2026 | 3.57% | 5.16M ADS | |
| Strategic holders2 holders · as of May 12, 2026 | 24.21% | 35.00M ADS | |
| Otherremainder | 59.17% | 85.55M ADS |
144.59M ADS (1 ADS = 1 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
37 holders · 18.87M shares · 7 new positions · 15 increased · 9 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 7.93M | 5.49% | 0 | May 15, 2026 |
| 683 Capital Management, LLC | 3.32M | 2.29% | 0 | May 15, 2026 |
| Bank of America Corp /DE/ | 1.98M | 1.37% | −500.0K | May 18, 2026 |
| Eversept Partners, LP | 1.76M | 1.22% | +1.3K | May 15, 2026 |
| Morgan Stanley | 1.18M | 0.81% | +114.3K | May 15, 2026 |
| Marshall Wace, LLP | 554.4K | 0.38% | +274.3K | May 15, 2026 |
| Raymond James Financial Inc | 395.8K | 0.27% | +3.8K | May 14, 2026 |
| Squarepoint Ops LLC | 302.0K | 0.21% | −22.4K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 11.70% | 7.93M | 13G | Feb 13, 2026 ↗ |
| TCG Crossover GP III, LLC | 9.80% | 14.50M | 13G | May 12, 2026 ↗ |
| Sirenia Capital Management LP | 6.10% | 8.91M | 13G | Aug 14, 2026 ↗ |
| Commodore Capital LP | 5.10% | 7.48M | 13G | Aug 17, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.